NICE Rejects J&J, AbbVie Leukemia Blockbuster Hopeful

Source: Reuters

Mar 03, 2016

Britain's healthcare cost-effectiveness agency, National Institute for Health and Care Excellence (NICE), has rejected Imbruvica, a potential breakthrough treatment for leukemia, jointly offered by J&J and AbbVie.

The agency expressed that it wasn't confident that Imbruvica, with a list price of $78,000 per year, represented an effective use of resources, despite the fact that J&J's Janssen is offering the treatment at a discount to the National Health Service.

Last year, AbbVie purchased Pharmacyclics, which had developed Imbruvica in partnership with J&J. The drug is first in a new class of cancer treament known as Burton's tyrosine kinase inhibitors.

Read the Reuters article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments